Last checked at | Director Dealings Summary - Week Ended April 2 | ||||||||||||
| Company | Name | Position | Number of Shares | Resulting Holding | *Note | GBP Value | ||||||
| BUYS | ||||||||||||
| RM2 International | John Walsh | CEO | 1.2 million | 22.2 million | 648,000 | |||||||
| London Capital Group | Charles-Henri Sabet | CEO | 125,000 | 6.9 million | 340,000 | |||||||
| Hutchison China | Simon To | Chairman | 18,000 | 69,000 | Same day as concept trial for cancer treatment met efficacy target. | 234,000 | ||||||
| Hutchison China | Edith Shih | Non-Executive | 18,000 | 48,000 | Same day as concept trial for cancer treatment met efficacy target. | 234,000 | ||||||
| Standard Life UK Smaller Co's | Allister Langlands | Director | 50,000 | 95,000 | 145,000 | |||||||
| Koovs | Waheed Alli | Chairman | 152,500 | 4.9 million | Same day as Koovs said it would spend more on marketing than anticapted. | 99,000 | ||||||
| Walker Crips | Sean Kin Wai Lam | MD | 221,000 | 422,996 | 95,000 | |||||||
| Walker Crips | Lim Hua Min | Non-Executive | 221,000 | 9.1 million | 95,000 | |||||||
| Monitise | Elizabth Buse | CEO | 500,000 | 1 million | One week after Monitise said it was no longer for sale deciding to remain an independent company. | 66,000 | ||||||
| Stanley Gibbons | Martin Bralsford | Chairman | 22,000 | 204,800 | Same day as profit warning. | 52,000 | ||||||
| Diploma | Andrew Smith | Non-Executive | 5,500 | Undisclosed | 45,000 | |||||||
| Indivior | Shaun Thaxter | CEO | 20,000 | 500,000 | 39,000 | |||||||
| Monitise | Tim Wade | Non-Executive | 250,000 | 350,000 | One week after Monitise said it was no longer for sale deciding to remain an independent company. | 35,000 | ||||||
| 7digital | Donald Cruickshank | Chairman | 140,000 | 290,000 | 24,000 | |||||||
| Synectics | David Coghlan | Chairman | 20,000 | 1.5 million | 23,000 | |||||||
| Plant Impact | John Brubaker | CEO | 40,000 | 646,000 | 21,000 | |||||||
| Mission Marketing | David Morgan | Chairman | 40,000 | 6.1 million | 17,000 | |||||||
| PuriCore | Charles Spicer | Chairman | 50,610 | 75,000 | 16,000 | |||||||
| Inspirit Energy | John Gunn | CEO | 2 million | 355 million | Same day as Inspirit said it will deliver its first micro-combined heat and power boiler to a major utility. | 13,000 | ||||||
| Barclays | John McFarlane | Incoming Chairman | 5,000 | 6,015 | Will become chairman at AGM on April 23. | 12,000 | ||||||
| LPA Goup | Per Staehr | Non-Executive | 15,000 | 185,500 | 11,000 | |||||||
| Progility | Hugh Crawley | CFO | 200,000 | 200,000 | Appointed last Friday. | 11,000 | ||||||
| superGroup | Euan Sutherland | CEO | 10,117 | 11,613 | 9,900 | |||||||
| Lavendon | John Coghlan | Non-Executive | 5,000 | 5,500 | 9600 | |||||||
| Aeorema Communications | Michael Hale | Chairman | 25,000 | 1.7 million | 6,900 | |||||||
| Churchill China | David Taylor | CFO | 1,000 | 21,000 | 6,000 | |||||||
| SOCO International | Anthony Maris | COO | 1,213 | 132,956 | 1,900 | |||||||
| SELLS | ||||||||||||
| Nostrum Oil & Gas | Frank Monstrey | Chairman | 18.7 million | 32.5 million | 2 days after Nostrum reported profit drop. | 109,000,000 | ||||||
| NAHL Group | Samantha Porteous | Non-Executive Director | 3.1 million | Nil | 3 days after NAHL reported profit drop in maiden results. | 7,600,000 | ||||||
| IHG | Tracy Robbins | Director | 28,047 | 183,997 | 738,000 | |||||||
| Michael Page | Oliver Watson | Director | 101,620 | Undisclosed | 540,000 | |||||||
| Jupiter Fund Management | Adrian Creedy | Company Secretary | 100,000 | 1.8 million | 414,000 | |||||||
| STV Group | Rob Woodward | CEO | 100,000 | 419,322 | 383,000 | |||||||
| Nichols | Peter Nichols | Chairman | 17,060 | 2.1 million | 201,000 | |||||||
| Tribal Group | Steve Breach | Finance Director | 81,296 | 172,728 | 2 weeks after Tribal swung to a loss. | 120,000 | ||||||
| Witan Investment Trust | Harry Henderson | Chairman | 2,100 | 722,732 | 17,000 | |||||||
| *Note: A recent company event around the time of the dealing does not suggest the dealing took place because of that event. When a spouse or related party to a director buys shares, the resulting holding is the beneficial holding of the director | ||||||||||||
| Contact: +44 207 199 0340; newsroom@alliancenews.com; @AllNewsTeam | ||||||||||||
| Copyright 2015 Alliance News Limited. All Rights Reserved. | ||||||||||||
10 Jul 2023 08:53
IN BRIEF: Hutchmed starts study for tumour treatment in China
Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases' treatment developer - Starts phase one study in China of its SHP2 inhibitor HMPL-415 for the treatment of advanced malignant solid tumours. First patient received their first dose on Thursday last week. Hutchmed expects up to 80 patients to take part in the study. SHP2 is a non-receptor protein tyrosine phosphatase which controls cell growth and cell migration.
Read more